 Jennifer Schuster
Concepts (283)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Tract Infections | 13 | 2022 | 68 | 4.020 |
Why?
| | Enterovirus Infections | 10 | 2022 | 29 | 3.310 |
Why?
| | Enterovirus D, Human | 10 | 2022 | 21 | 3.260 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2023 | 45 | 3.200 |
Why?
| | Humans | 71 | 2023 | 6128 | 2.850 |
Why?
| | Child | 50 | 2023 | 2874 | 2.610 |
Why?
| | Metapneumovirus | 9 | 2022 | 12 | 2.470 |
Why?
| | Paramyxoviridae Infections | 8 | 2016 | 12 | 2.380 |
Why?
| | Influenza, Human | 8 | 2023 | 45 | 2.370 |
Why?
| | Influenza Vaccines | 7 | 2023 | 18 | 2.240 |
Why?
| | Child, Preschool | 31 | 2022 | 1459 | 2.180 |
Why?
| | Hospitalization | 20 | 2022 | 179 | 2.060 |
Why?
| | Disease Outbreaks | 10 | 2022 | 24 | 1.940 |
Why?
| | United States | 29 | 2023 | 640 | 1.870 |
Why?
| | Rhinovirus | 4 | 2022 | 9 | 1.660 |
Why?
| | Antibodies, Viral | 6 | 2022 | 37 | 1.630 |
Why?
| | Adolescent | 32 | 2023 | 1976 | 1.570 |
Why?
| | Virus Diseases | 2 | 2020 | 12 | 1.490 |
Why?
| | Female | 30 | 2023 | 3367 | 1.400 |
Why?
| | Infant | 25 | 2022 | 1399 | 1.400 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 5 | 2021 | 9 | 1.370 |
Why?
| | Systemic Inflammatory Response Syndrome | 9 | 2022 | 14 | 1.320 |
Why?
| | Male | 28 | 2023 | 3284 | 1.310 |
Why?
| | Gastroenteritis | 2 | 2022 | 22 | 1.050 |
Why?
| | Vaccination | 9 | 2022 | 49 | 1.050 |
Why?
| | Transplants | 1 | 2023 | 2 | 0.980 |
Why?
| | Viruses | 2 | 2022 | 5 | 0.940 |
Why?
| | Antibodies, Neutralizing | 5 | 2021 | 31 | 0.940 |
Why?
| | Communicable Diseases | 2 | 2022 | 6 | 0.930 |
Why?
| | Vulnerable Populations | 1 | 2022 | 5 | 0.920 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 17 | 0.920 |
Why?
| | Touch | 1 | 2021 | 4 | 0.910 |
Why?
| | Pandemics | 8 | 2023 | 65 | 0.910 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 19 | 0.910 |
Why?
| | School Health Services | 1 | 2022 | 10 | 0.910 |
Why?
| | Influenza A Virus, H1N1 Subtype | 4 | 2022 | 9 | 0.910 |
Why?
| | Respiratory System | 1 | 2021 | 5 | 0.910 |
Why?
| | Prospective Studies | 11 | 2022 | 475 | 0.860 |
Why?
| | Immunization Schedule | 2 | 2017 | 7 | 0.830 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 4 | 0.820 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2022 | 22 | 0.790 |
Why?
| | Hematologic Diseases | 1 | 2018 | 4 | 0.730 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 9 | 0.730 |
Why?
| | Critical Care | 4 | 2021 | 13 | 0.730 |
Why?
| | Picornaviridae Infections | 1 | 2018 | 18 | 0.710 |
Why?
| | Communicable Diseases, Emerging | 1 | 2018 | 3 | 0.700 |
Why?
| | Communicable Disease Control | 1 | 2018 | 7 | 0.700 |
Why?
| | Hyponatremia | 1 | 2017 | 2 | 0.690 |
Why?
| | Immunoglobulins, Intravenous | 4 | 2021 | 8 | 0.690 |
Why?
| | Vaccines | 1 | 2017 | 13 | 0.660 |
Why?
| | Public Health Practice | 1 | 2016 | 1 | 0.640 |
Why?
| | Neoplasms | 1 | 2018 | 96 | 0.640 |
Why?
| | Immunization Programs | 1 | 2016 | 6 | 0.640 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2020 | 38 | 0.630 |
Why?
| | Infectious Disease Medicine | 2 | 2022 | 2 | 0.620 |
Why?
| | Case-Control Studies | 9 | 2022 | 130 | 0.620 |
Why?
| | Coronavirus Infections | 3 | 2020 | 16 | 0.580 |
Why?
| | Specialization | 1 | 2014 | 7 | 0.560 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 29 | 0.530 |
Why?
| | Retrospective Studies | 8 | 2022 | 1196 | 0.530 |
Why?
| | Hospitals, Pediatric | 6 | 2022 | 179 | 0.520 |
Why?
| | Treatment Outcome | 6 | 2021 | 624 | 0.520 |
Why?
| | Meningitis, Fungal | 1 | 2013 | 1 | 0.510 |
Why?
| | Histoplasma | 1 | 2013 | 3 | 0.510 |
Why?
| | Adult | 6 | 2022 | 1107 | 0.510 |
Why?
| | Schools | 3 | 2022 | 38 | 0.510 |
Why?
| | Histoplasmosis | 1 | 2013 | 3 | 0.510 |
Why?
| | Pediatrics | 1 | 2014 | 175 | 0.470 |
Why?
| | Nervous System Diseases | 2 | 2023 | 17 | 0.460 |
Why?
| | Fever | 4 | 2021 | 27 | 0.450 |
Why?
| | Population Surveillance | 2 | 2021 | 12 | 0.450 |
Why?
| | Myelitis | 2 | 2022 | 3 | 0.440 |
Why?
| | Infliximab | 2 | 2021 | 5 | 0.420 |
Why?
| | Vaccines, Synthetic | 4 | 2022 | 9 | 0.410 |
Why?
| | Prevalence | 2 | 2020 | 137 | 0.400 |
Why?
| | Longitudinal Studies | 2 | 2020 | 131 | 0.400 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2022 | 8 | 0.390 |
Why?
| | Risk Factors | 3 | 2015 | 393 | 0.380 |
Why?
| | Seasons | 5 | 2022 | 18 | 0.370 |
Why?
| | Asthma | 3 | 2022 | 138 | 0.350 |
Why?
| | Infant, Newborn | 7 | 2022 | 887 | 0.340 |
Why?
| | Severity of Illness Index | 2 | 2020 | 150 | 0.330 |
Why?
| | Advisory Committees | 2 | 2017 | 9 | 0.330 |
Why?
| | Animals | 5 | 2016 | 896 | 0.310 |
Why?
| | Length of Stay | 4 | 2020 | 237 | 0.300 |
Why?
| | Critical Illness | 2 | 2022 | 22 | 0.290 |
Why?
| | Intensive Care Units | 2 | 2022 | 17 | 0.290 |
Why?
| | Minority Groups | 2 | 2022 | 18 | 0.290 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2022 | 29 | 0.290 |
Why?
| | Public Health Surveillance | 2 | 2021 | 4 | 0.270 |
Why?
| | Disease Models, Animal | 2 | 2014 | 80 | 0.270 |
Why?
| | Glucocorticoids | 2 | 2021 | 34 | 0.270 |
Why?
| | Acute Disease | 2 | 2022 | 65 | 0.260 |
Why?
| | Echocardiography | 3 | 2020 | 58 | 0.260 |
Why?
| | Neuromuscular Diseases | 2 | 2022 | 4 | 0.260 |
Why?
| | Central Nervous System Viral Diseases | 2 | 2022 | 4 | 0.260 |
Why?
| | Immunoglobulin G | 2 | 2021 | 34 | 0.250 |
Why?
| | Guillain-Barre Syndrome | 1 | 2023 | 1 | 0.250 |
Why?
| | Stroke | 1 | 2023 | 17 | 0.240 |
Why?
| | Regression Analysis | 2 | 2021 | 60 | 0.240 |
Why?
| | Rotavirus | 1 | 2022 | 9 | 0.230 |
Why?
| | Age Factors | 3 | 2021 | 220 | 0.230 |
Why?
| | Coinfection | 1 | 2022 | 5 | 0.230 |
Why?
| | Rotavirus Infections | 1 | 2022 | 13 | 0.230 |
Why?
| | Rotavirus Vaccines | 1 | 2022 | 11 | 0.230 |
Why?
| | Neutralization Tests | 3 | 2022 | 6 | 0.230 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2022 | 1 | 0.230 |
Why?
| | Academic Medical Centers | 1 | 2022 | 10 | 0.230 |
Why?
| | Disabled Children | 1 | 2022 | 7 | 0.230 |
Why?
| | Community-Institutional Relations | 1 | 2022 | 9 | 0.230 |
Why?
| | Child, Hospitalized | 1 | 2022 | 27 | 0.230 |
Why?
| | Education, Distance | 1 | 2022 | 4 | 0.230 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2020 | 89 | 0.230 |
Why?
| | Urban Population | 1 | 2022 | 34 | 0.230 |
Why?
| | Herpesvirus 1, Cercopithecine | 1 | 2021 | 2 | 0.220 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2021 | 40 | 0.220 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2021 | 14 | 0.220 |
Why?
| | Follow-Up Studies | 2 | 2021 | 308 | 0.220 |
Why?
| | Vaccine Potency | 1 | 2021 | 7 | 0.220 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 117 | 0.210 |
Why?
| | Immunocompromised Host | 1 | 2020 | 9 | 0.210 |
Why?
| | Mouth | 1 | 2020 | 3 | 0.210 |
Why?
| | DNA, Viral | 1 | 2020 | 14 | 0.200 |
Why?
| | Monitoring, Physiologic | 1 | 2020 | 23 | 0.200 |
Why?
| | Postoperative Care | 1 | 2020 | 29 | 0.200 |
Why?
| | Prognosis | 1 | 2020 | 179 | 0.190 |
Why?
| | Risk Assessment | 1 | 2020 | 132 | 0.190 |
Why?
| | Biomarkers | 2 | 2021 | 118 | 0.190 |
Why?
| | Cough | 2 | 2015 | 7 | 0.190 |
Why?
| | Diagnosis, Differential | 2 | 2021 | 75 | 0.180 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2015 | 7 | 0.180 |
Why?
| | Metabolic Diseases | 1 | 2018 | 13 | 0.180 |
Why?
| | Virus Replication | 2 | 2015 | 7 | 0.180 |
Why?
| | Recurrence | 2 | 2021 | 106 | 0.180 |
Why?
| | Reassortant Viruses | 1 | 2018 | 1 | 0.180 |
Why?
| | Orthomyxoviridae | 1 | 2018 | 2 | 0.180 |
Why?
| | Organoplatinum Compounds | 1 | 2017 | 1 | 0.170 |
Why?
| | Sodium | 1 | 2017 | 7 | 0.170 |
Why?
| | Hypotension | 1 | 2017 | 4 | 0.170 |
Why?
| | Young Adult | 4 | 2022 | 594 | 0.170 |
Why?
| | Influenza B virus | 3 | 2022 | 21 | 0.170 |
Why?
| | Patient Acuity | 3 | 2022 | 8 | 0.170 |
Why?
| | Yellow Fever Vaccine | 1 | 2017 | 1 | 0.170 |
Why?
| | Meningococcal Vaccines | 1 | 2017 | 2 | 0.170 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2017 | 3 | 0.170 |
Why?
| | Herpes Zoster Vaccine | 1 | 2017 | 2 | 0.170 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2017 | 3 | 0.170 |
Why?
| | Hepatitis B Vaccines | 1 | 2017 | 2 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 87 | 0.170 |
Why?
| | Papillomavirus Vaccines | 1 | 2017 | 8 | 0.160 |
Why?
| | Pneumococcal Vaccines | 1 | 2017 | 14 | 0.160 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 97 | 0.160 |
Why?
| | Pregnancy | 3 | 2022 | 252 | 0.160 |
Why?
| | Mutation | 1 | 2018 | 202 | 0.160 |
Why?
| | Societies, Medical | 1 | 2016 | 44 | 0.160 |
Why?
| | Replicon | 1 | 2016 | 1 | 0.150 |
Why?
| | Recombination, Genetic | 1 | 2015 | 4 | 0.150 |
Why?
| | Virus Internalization | 1 | 2015 | 1 | 0.150 |
Why?
| | Jordan | 1 | 2015 | 1 | 0.150 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 5 | 0.150 |
Why?
| | Viral Vaccines | 1 | 2016 | 10 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2015 | 8 | 0.150 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2015 | 1 | 0.150 |
Why?
| | Disease Management | 1 | 2015 | 36 | 0.140 |
Why?
| | Interferon Type I | 1 | 2015 | 2 | 0.140 |
Why?
| | Community Networks | 1 | 2014 | 2 | 0.140 |
Why?
| | Cross Protection | 1 | 2014 | 1 | 0.140 |
Why?
| | Seroepidemiologic Studies | 1 | 2014 | 3 | 0.140 |
Why?
| | Disease Transmission, Infectious | 1 | 2014 | 11 | 0.140 |
Why?
| | Emergency Medical Services | 1 | 2014 | 14 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 25 | 0.140 |
Why?
| | Physicians | 1 | 2014 | 21 | 0.140 |
Why?
| | Mice, Inbred DBA | 1 | 2014 | 3 | 0.140 |
Why?
| | Chemoprevention | 1 | 2014 | 4 | 0.140 |
Why?
| | Genetic Variation | 1 | 2015 | 142 | 0.140 |
Why?
| | Mice, Inbred BALB C | 1 | 2014 | 29 | 0.140 |
Why?
| | Lung | 1 | 2015 | 92 | 0.140 |
Why?
| | Immunotherapy | 1 | 2014 | 15 | 0.130 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 140 | 0.130 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2013 | 2 | 0.130 |
Why?
| | Virulence | 1 | 2013 | 6 | 0.130 |
Why?
| | Opportunistic Infections | 1 | 2013 | 7 | 0.130 |
Why?
| | Signal Transduction | 1 | 2015 | 151 | 0.130 |
Why?
| | Bronchiolitis | 1 | 2013 | 11 | 0.130 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 103 | 0.130 |
Why?
| | Disease Progression | 1 | 2013 | 93 | 0.130 |
Why?
| | Radiography | 1 | 2013 | 37 | 0.130 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 99 | 0.130 |
Why?
| | Chronic Disease | 1 | 2013 | 111 | 0.120 |
Why?
| | Brain | 1 | 2013 | 92 | 0.120 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 286 | 0.120 |
Why?
| | Viral Fusion Proteins | 3 | 2016 | 4 | 0.110 |
Why?
| | Inflammation | 2 | 2023 | 48 | 0.110 |
Why?
| | Patient Discharge | 2 | 2022 | 59 | 0.110 |
Why?
| | Immunomodulation | 2 | 2021 | 2 | 0.110 |
Why?
| | Cohort Studies | 2 | 2022 | 256 | 0.110 |
Why?
| | Emergency Service, Hospital | 2 | 2022 | 123 | 0.100 |
Why?
| | Respiration, Artificial | 2 | 2020 | 32 | 0.090 |
Why?
| | Flow Cytometry | 2 | 2015 | 30 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2015 | 130 | 0.070 |
Why?
| | Mice | 2 | 2015 | 453 | 0.060 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2023 | 1 | 0.060 |
Why?
| | Receptor, Notch1 | 1 | 2023 | 2 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 4 | 0.060 |
Why?
| | Adenoviridae | 1 | 2022 | 6 | 0.060 |
Why?
| | Antigens, Viral | 1 | 2022 | 7 | 0.060 |
Why?
| | Immunoassay | 1 | 2022 | 10 | 0.060 |
Why?
| | Oxygen | 1 | 2022 | 24 | 0.060 |
Why?
| | Aftercare | 1 | 2022 | 4 | 0.060 |
Why?
| | Policy | 1 | 2022 | 3 | 0.060 |
Why?
| | Viral Envelope Proteins | 1 | 2022 | 3 | 0.060 |
Why?
| | Vaccines, Attenuated | 1 | 2022 | 8 | 0.060 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 11 | 0.060 |
Why?
| | Inpatients | 1 | 2023 | 51 | 0.060 |
Why?
| | Immunization, Passive | 1 | 2022 | 1 | 0.060 |
Why?
| | Life Support Care | 1 | 2022 | 1 | 0.060 |
Why?
| | Immunization, Secondary | 1 | 2022 | 2 | 0.060 |
Why?
| | Pilot Projects | 1 | 2022 | 123 | 0.060 |
Why?
| | Mothers | 1 | 2022 | 34 | 0.060 |
Why?
| | Saliva | 1 | 2021 | 9 | 0.060 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2022 | 28 | 0.060 |
Why?
| | Specimen Handling | 1 | 2021 | 18 | 0.060 |
Why?
| | Nasopharynx | 1 | 2021 | 24 | 0.060 |
Why?
| | Propensity Score | 1 | 2021 | 11 | 0.060 |
Why?
| | Shock | 1 | 2021 | 4 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 42 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 52 | 0.050 |
Why?
| | Obesity | 1 | 2022 | 116 | 0.050 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2021 | 8 | 0.050 |
Why?
| | Stroke Volume | 1 | 2021 | 13 | 0.050 |
Why?
| | Comorbidity | 1 | 2021 | 67 | 0.050 |
Why?
| | Logistic Models | 1 | 2021 | 92 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2021 | 180 | 0.050 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 9 | 0.050 |
Why?
| | Hospital Costs | 1 | 2020 | 27 | 0.050 |
Why?
| | International Classification of Diseases | 1 | 2020 | 8 | 0.050 |
Why?
| | Drug Resistance | 1 | 2019 | 7 | 0.050 |
Why?
| | Inflammation Mediators | 1 | 2019 | 8 | 0.050 |
Why?
| | Time Factors | 1 | 2020 | 273 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 6 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2019 | 31 | 0.050 |
Why?
| | Practice Patterns, Nurses' | 1 | 2017 | 5 | 0.040 |
Why?
| | Algorithms | 1 | 2017 | 98 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 79 | 0.040 |
Why?
| | Alphavirus | 1 | 2016 | 1 | 0.040 |
Why?
| | Encephalitis Virus, Venezuelan Equine | 1 | 2016 | 1 | 0.040 |
Why?
| | Nose | 1 | 2016 | 7 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2016 | 16 | 0.040 |
Why?
| | Sequence Homology | 1 | 2015 | 2 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2015 | 3 | 0.040 |
Why?
| | Endosomes | 1 | 2015 | 1 | 0.040 |
Why?
| | Bronchi | 1 | 2015 | 2 | 0.040 |
Why?
| | Genome, Viral | 1 | 2015 | 4 | 0.040 |
Why?
| | Microscopy, Confocal | 1 | 2015 | 3 | 0.040 |
Why?
| | Molecular Epidemiology | 1 | 2015 | 6 | 0.040 |
Why?
| | Transfection | 1 | 2015 | 32 | 0.040 |
Why?
| | Phylogeny | 1 | 2015 | 19 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2015 | 15 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2015 | 30 | 0.040 |
Why?
| | Illinois | 1 | 2015 | 4 | 0.040 |
Why?
| | Dyspnea | 1 | 2015 | 5 | 0.040 |
Why?
| | Colorado | 1 | 2015 | 9 | 0.040 |
Why?
| | Respiratory Sounds | 1 | 2015 | 7 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 120 | 0.040 |
Why?
| | Cell Line | 1 | 2015 | 105 | 0.040 |
Why?
| | Lymphocyte Depletion | 1 | 2015 | 1 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 3 | 0.040 |
Why?
| | Viral Matrix Proteins | 1 | 2015 | 2 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2015 | 22 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2015 | 32 | 0.040 |
Why?
| | Missouri | 1 | 2015 | 83 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2015 | 115 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2015 | 53 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 102 | 0.040 |
Why?
| | Receptors, Virus | 1 | 2015 | 2 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2015 | 2 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 83 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2015 | 28 | 0.040 |
Why?
| | Oximetry | 1 | 2015 | 9 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 34 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2015 | 101 | 0.030 |
Why?
| | Aged | 1 | 2015 | 304 | 0.030 |
Why?
| | Middle Aged | 1 | 2015 | 557 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|